See ratings and reviews when you sign up for an account.

A Randomized, Double-blind, Single-center, Placebo Controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults With Seasonal Allergic Rhinitis (ITN043AD)

This study is currently Recruiting

April 2011 By National Institute of Allergy and Infectious Diseases (NIAID)

First Recieved on April 8, 2011

Last Updated on April 21, 2011

Sponsor: University of California, San Francisco
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
Identifier: NCT01335139


The purpose of this research study is to investigate whether sublingual immunotherapy (SLIT, grass pollen tablets under the tongue) has long term effects in severe hay fever.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - A clinical history of grass pollen-induced allergic rhinoconjunctivitis for at least 2 years with peak symptoms in May, June, or July. - A clinical history of moderate - severe rhinoconjunctivitis symptoms interfering with usual daily activities or with sleep as defined according to the ARIA classification of rhinitis. - A clinical history of rhinoconjunctivitis for at least 2 years requiring treatment with either antihistamines or nasal corticosteroids during the grass pollen season. - Positive skin prick test response, defined as wheal diameter greater than or equal to 3 mm, to Phleum pratense. - Positive specific IgE, defined as greater than or equal to IgE class 2 (0.7 kU/L), against Phleum pratense. - A positive response to nasal allergen challenge with Phleum pretense, defined as an increase in TNSS greater than or equal to 7 points above baseline. - For women of childbearing age, a willingness to use an effective form of contraception for the duration of the trial. - The ability to give informed consent and comply with study procedures. Exclusion Criteria: - Prebronchodilator FEV1 less than 70% of predicted value at either screening or baseline visit. - A clinical history of moderate - severe allergic rhinitis, according to the ARIA classification, due to tree pollen near or overlapping the grass pollen season.1 - A clinical history of persistent asthma and/or requiring regular inhaled corticosteroids for > 4 weeks per year outside of the grass pollen season. - A clinical history of moderate- severe allergic rhinitis, according to the ARIA classification, caused by an allergen to which the participant is regularly exposed.1 - History of emergency visit or hospital admission for asthma in the previous 12 months. - History of chronic obstructive pulmonary disease. - History of significant recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment. - History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness. - At randomization, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media, or other relevant infectious process; serous otitis media is not an exclusion criterion. Participants may be re-evaluated for eligibility after symptoms resolve. - Any tobacco smoking within the last 6 months or a history of greater than or equal to 10 pack years. - Previous treatment by immunotherapy with grass pollen allergen within the previous 5 years. - Any history of grade 4 anaphylaxis due to any cause as defined by the WAO grading criteria for immunotherapy (see appendix 7). - History of bleeding disorders or treatment with anticoagulation therapy - History of anti-IgE monoclonal antibody treatment. - Ongoing systemic immunosuppressive treatment. - History of intolerance to the study therapy, rescue medications, or their excipients. - For women of childbearing age a positive serum or urine pregnancy test with sensitivity of less than 50 mIU/mL within 72 hours before the start of study therapy. - The use of any investigational drug within 30 days of the screening visit. - The presence of any medical condition that the investigator deems incompatible with participation in the trial.


  • Investigator: Stephen Durham, MD - Study Chair - Imperial College London


  • Royal Brompton Hospital

    London, SW3 6LY United Kingdom

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.